secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001104659-26-036386
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis Phase 3 envudeucitinib hits PASI 90/100 endpoints in plaque psoriasis
----------------------------------------------------------------------------

- PASI 90 at Week 24: 68.0% (ONWARD1) and 62.1% (ONWARD2); PASI 100: 41.0% and 39.5%.
- Early onset: PASI 90 separation vs placebo by Week 4; itch relief by Week 2; scalp clearance in ~30% by Week 4.
- Safety profile consistent with Phase 2; no new signals, mainly mild AEs (headache, nasopharyngitis, URTI, acne).
- Company to submit NDA to FDA in H2 2026; Phase 3 long-term extension (ONWARD3) ongoing.
- Also evaluating envudeucitinib in SLE LUMUS Phase 2b with topline data expected Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/0001104659-26-036386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-036386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer